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Background/Aims: Use of placebo is the ideal for comparison in clinical trials to reduce biases. With
digital technology being used more frequently in healthcare interventions, how do we determine the
placebo effect where interventions exploit technology? If placebo in medicine is traditionally defined
by a lack of pharmacological agents, how might we begin to move towards controlling for effects of
digital technology?
Method: This paper explores the traditional placebo effect and discusses its impact in healthcare
contexts with digital technology with reference to a particular trial. Different meanings of placebo in
the context of evaluating technology suggest new challenges and positive consequences.
Results: Methodological considerations are discussed, which enabled the development of a placebo-
controlled evaluation of a digital technology in healthcare and rehabilitation.
Conclusion: Digital placebo was controlled in our trial by employing technology across all groups in
the absence of evidence-based practice and shows how to control for unknown and hidden effects of
technology.
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Introduction
As digital technology becomes more personalized1,2
and is able to record and represent richer informa-
tion about the body, the demands we place upon it in
trials and in medicine will increase. Digital technol-
ogy in health care settings is already set to increase
in three ways: a) wireless sensing b) sequencing
the genome and c) imaging and printing organs.3
These will enable further capture and investigation
of individual data such as blood glucose or blood
pressure, or capturing responses to therapy in
real-time.3 As the volume of research with digital
technology and mobiles increases, methodology
will need to adapt and become more robust.
Where possible, interventions evaluated using the
gold standard of double blind randomized controlled
trials often employ placebos as an effective counter-
measure to context and subjectivity. Placebo is
the purposeful null effect of an intervention and is
usually employed in opposition to an active technol-
ogy e.g. therapy, within a clinical trial. However, use
of placebo in interventional trials where digital
technologies such as mobiles are used, requires
evaluation, and as yet there is no clearly established
methodology. In complex interventions with
digital technology, rigorous evaluation is needed,
and traditional placebo alters due to demands
placed on trial fidelity.
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This paper is based on our experiences and reflec-
tions from our own evaluation of placebo during the
development of an NIHR feasibility trial using a
commercial device for children with cerebral palsy
(ISRCTN17624388; IRAS ethics approval 14 NW
1499). Our study, just completed, explored the
potential of utilising a widely available commercial
games console (the Nintendo Wii Fit) within the
home to deliver regular, tailored physiotherapy
schedules of Virtual Reality Therapy (VRT) for
children with cerebral palsy in comparison to free
play usage. Participating families completed an
online questionnaire regarding children’s current
use of computer games such as Nintendo Wii Fit
within the home. They were then randomised into
either a supported or unsupported (control) partici-
pant group. Supported participants followed a
therapist prescribed schedule over a 12-week period,
utilising only specified Nintendo Wii Fit games for
designated amounts of time per session. Sessions
lasted 30 minutes, undertaken three times a week
with games selected for specific physiotherapy pur-
poses, such as core stability or balance. During this
12-week period, bi-weekly telephone contact to
families oversaw the child’s progress, updated game
selection and responded to any queries. Parent,
carers, and children were required to keep a simple
daily diary to rate sessions. Unsupported (control)
participants used the Nintendo Wii Fit for 30-minute
sessions, 3 times a week, over a 12-week period.
However, they had a free choice over which games
they chose and the duration of each game played
within the session. Bi-weekly phone contact was
also made during the 12-week period. Parents and
children were also requested to keep a simple daily
diary to rate sessions. Assessments of balance and
functional mobility were taken at three time-points:
before commencing the trial, halfway through, and
on completion. An exit questionnaire asked parents
and children to report on factors such as engage-
ment, ease of use and fatigue.
In each section of this article we return to our study
to provide grounded examples. First we discuss our
study as a context for where the placebo effect fits
into complex interventions incorporating digital
technology. Second, we discuss placebo, its history
and use in clinical trials is discussed. Placebo
constraints are made up of four factors: a) the
placebo effect, b) the placebo delivery c) the placebo
object, and d) the way in which placebo controlled
trials measure output. Last, we give further examples
of where the placebo with digital technology has been
tried and could have a medical application. There are
as yet few examples of this type of intervention trial,
but given the potential for growth with digital
technology, especially with mobiles, this is set to
increase.3 Our examples show different contexts
and types of research incorporating digital technolo-
gy where placebo effects are tackled or controlled.
We conclude by conjecturing as to whether complex
interventions using digital technology will enable the
appropriate construction of placebos and enable fair
comparisons.
A Complex Intervention and Placebo
Complex interventions require careful planning
around the practical effectiveness of an interven-
tion, how the intervention exerts its effect and how
interactions between components change across
intervention groups.6 An effective intervention that
produces meaningful outcomes may change
completely if there is additional impact of technol-
ogy on placebo.
For our study, a traditional control group of ‘‘best
pre-existing current treatment’’ (most likely standard
physiotherapy) therefore was considered a difficult
option due to the current lack of understanding of a
placebo effect with technology.4 For example, other
factors e.g. the Hawthorne effect or observational
bias may occur as a result of simply being watched
during an intervention. The actual impact of using
digital technology is not as yet known, comparing a
virtual reality group with a group without virtual
reality is an option but could have overstated
benefits. A comparison group considered children
standing on a wobble board, whilst watching a video
of the sports/activities that would be played on the
gaming system on a large screen. This option was
close to the digital version, but was comparing a
digital with a non-digital version.
However it was decided that both groups would have
to be given the digital technology but with subtle
differences between groups, as there was no way to
control for hidden effects of the digital technology.
Group ‘A’ became a supported therapy group, with a
prescribed programme of therapeutically oriented
games for targeted skeletal-muscle groups, a sug-
gested number of times per week for activity, and bi-
weekly phone calls by a physiotherapist. Group ‘B’
became an unsupported group with un-prescribed
access to the console, with suggested number of times
per week for activity on the console, and bi-weekly
phone calls from research staff to see how the
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participants were progressing, but without offering
structured or scaffolded learning support.
Our choices regarding trial groups were altered
because of the possibility of hidden and unforeseen
effects of technology that led us to ask: What
constitutes placebo? What are the wider implica-
tions for placebo with complex interventions when
digital technology is incorporated? What implica-
tions does this have on fair comparison in complex
interventions? We now address these questions by
looking at the constituent parts of the placebo
effect, its delivery, the object that is the focus of the
placebo, and how hidden effects get measured or
are controlled.
What is a placebo?
A placebo is often used to find out whether a
treatment has real or just perceived benefits. Placebo
has been shown to be in some cases as powerful as an
active intervention or drug and ‘‘conveys meaning,
influences expectations and possibly triggers condi-
tioned responses or behaviour changes’’11, so that
‘‘[t]he simple act of receiving any treatment (active
or not) may in itself, be efficacious because of
expectation of benefit’’.10,12 This meaning has gradu-
ally been extended to include receiving, or simply
seeking medical attention, and can sometimes be
enough to help patients recover.13
Doctors have often realised that illness can be self-
limiting, and so may give an inactive treatment, with
the outcome being that a patient might benefit
psychologically. Medically the term has been in use
from as early as 1772, with the term entering the
medical lexicon increasingly in the 19th century.
Placebo can account for as much as 30-40% of
patient relief for ailments such as pain, blood
pressure, asthma, and coughs.14 What is unclear is
how placebo actually works. Factors as strange as
drug packaging can impact on effectiveness.4 The
placebo effect is a conglomeration of effects rather
than any single entity. Brissonnet15, suggests that
literature on the subject of placebo prior to 1996
may even be faulty, as our understanding of placebo
was incomplete, and whilst Brissonet is concerned
with medical placebo the observation is appropriate
given the subsequent growth of mobile and digital
technology. Yet, the significance of placebo is such
that Curie et al (2015) report that even for indivi-
duals with an intellectual disability they are still
effective, warning of dangers ‘‘when testing novel
treatments’’ due to contextual factors.31 Curie et al
also suggest limits to the impact of placebo as
individuals with co-morbid dementia showed no
placebo response, whilst the higher an intelligence
quotient score the greater the likelihood of response.
For our Virtual Reality feasibility study, the simple
act of using a commercial console by children may
well have been enough to obtain functional improve-
ment but this is further complicated by benefits of
the therapeutic programme or natural development
with age. Further, if individuals and families are
biased toward the benefits of digital technology or
mobile smartphone use, this may change attitudes,
opinions, perceptions, and outcomes with techno-
logical intervention, even if there is no actual benefit.
The use of digital technology makes it difficult to
identify those causal factors that can cause positive
change.
Placebo is an umbrella term
Placebo in healthcare evaluations is complex, and
can be thought to comprise three key elements: the
effect, the delivery and the object.
1) The Placebo Effect.
Placebo effects occur because of the feeling or
perception that an intervention is working and has
associated wellbeing, which is produced by the
placebo, pure or pseudo.15 Homeopathic treatments
are a good example of pure placebo, as described in
Ben Goldacre’s book Bad Science4, as the chemicals
are on the whole dummy treatments. A placebo
effect is problematic however, as a lack of active
ingredient somehow causes physical change.16
Placebo is inert, so the placebo effect is also rather
referred to as a meaning response.16 For example,
studies where there is an effect of the placebo such as
blue pills being judged as depressants, and red pills
being seen as dangerous, subsequently participants
experience exactly that - a blue pill depressing a
participant, a red pill judged as danger, it is highly
likely that the same effects may occur with company
names, or the colour of mobile phones.16 Meaning
response permeates all interactions between clini-
cian and patient, such as manner, language, dress,
diagnosis, and prognosis.16 Therefore, ‘placebo
effect’ refers to the meaning response from the
participant that is desirable and is under investiga-
tion. Meaning response that is undesirable and not
under investigation is now commonly referred to as
the ‘‘nocebo effect’’.17 For example, inert treatments
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not under investigation and that produce endoge-
nous opiates in participants would be nocebo.16
Complex interventions that incorporate digital
technology may result in a potential meaning
response with associated wellbeing. For example,
the simple presence of a commercial console (e.g.
Wii Fit) may change beliefs and attitudes about its
effectiveness as a therapeutic device, producing a
desired outcome based on feelings or perceptions
that the technology is going to have an effect. But it
would be vital to know what element of meaning
response is under investigation, especially when
the active elements of digital technology are still
unclear.
2) The Placebo Delivery.
If placebo effect is constructed from wanted and
unwanted meaning response constructed through
interaction, how placebo is given or delivered to the
participant or patient is also important. This is the
who, where, and when of the placebo, and not only
includes the meaning response generated by the
doctor or health professional, but also includes the
context in which the placebo is given, the immediate
timing of the placebo, and the perception of inter-
ventions over time. Context effects and impacts in
medicine, so-called ’optimal healing environments’
are well researched, and include factors such as
expectations to treatment and empathy.11,16 For
example, delivery tends to work better if a drug is
subcutaneously injected as opposed to taken orally,
it is also better if given with empathy rather than
neutral manner.11,18 Placebo effects are also larger
when the mode of delivery is physical (see the
placebo object below), as opposed to pharmacologi-
cal or psychological.19 Placebo delivery with digital
technology is as much to do with rituals, or activities
that routinely occur in a set order, as well as ideas
surrounding computers and mobile technology
during interaction that surrounds patient consulta-
tion.13 Delivery is not limited to a clinical setting, as
seen by advances in tele-health care, as mobile
delivered interventions are more likely to occur in
the home, which may or may be not be considered an
optimal healing environment for complex interven-
tions incorporating digital technology. The place,
timing, and delivery of therapy with a commercial
console or piece of equipment for example will
therefore further complicate the impact of technolo-
gy. Recent evidence on the impact of mobile phone
screens on melatonin and sleep levels shows how
physical response is genuinely affected, linking the
bluer end of the light spectrum used in screen
devices to common alert states of behavior.33,34
In our study we were using the commercial console
in the home. Use in the home may change the
clinical effect of the console, as the clinical relation-
ship of patient-health professional has been
removed, as has the time of day when the technology
may be used, creating further possible positive or
negative effects.
3) The Placebo Object.
Placebo effect is the ‘meaning response’ (see section
1 above) under investigation; the delivery is the
manner in which the agent causing change is
transferred to the participant. The placebo object is
the focus of the intervention i.e. the drug, therapeutic
intervention (e.g. needle in acupuncture), packaging,
smartphone, or machine that might be used in a
clinical trial. This overlaps somewhat with the
meaning response but focuses on the physicality of
an object, referring to the attributes and expectations
given to a particular object. The object at the heart
of the intervention can be vested with a wide variety
of meaning response, from a needle  potentially
negative  to positive such as the colour of packaging
on a headache or smartphone tablet box implying
cleanliness, purity or relief from symptoms. The
physical object that is the focus of the placebo may
well alter with the type of digital technology. If a
placebo object is a computer or mobile phone,
then the type, (e.g. familiar, novel, bespoke, ‘off-
the-shelf’, old) of computer becomes important.
Computers such as a desktop, a smartphone, a
tablet, a Radio Frequency Identification (RFID)
tag, or a smart-object all change the dynamics of
interaction. If a patient-clinician relationship alone
improves outcomes13, a patient-object (e.g. the
computer) relationship may also improve or worsen
outcomes similar to how tools like stethoscopes are
considered an important part of clinical rituals.13
The object, when presented in the right clinical way,
vested with important attributes such as validated
tests, becomes imbibed with clinical meaning.2022
For digital technology such as smartphones, the
value of placebo as an object, exposes the impor-
tance of what Gibson called object affordance, or the
perceptual cues and clues that imply how the object
will be used.22 For our feasibility study it may be that
positive outcomes could be explained away simply
because we made the console the subject of a health
study.
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Once the placebo is delivered through an object like
a smartphone we have then selection of criteria
applicable to establish a placebo:
1. Placebo effect or meaning response i.e. the
feelings and perceptions that individuals have
of the placebo/intervention
2. Placebo delivery: The interaction that
occurs during the delivery of the placebo/
intervention
3. The physical object itself e.g. the mobile
element such as a smart phone
All three need careful consideration if mobile
technology delivers a medical intervention. It may
be prudent to survey participant’s attitudes and
perceptions toward mobile technology itself prior to
data collection, or have attitudes specified as com-
plicating factors in analysis plans. Internet and
mobile addiction could for example confound re-
sults if as recently found, individuals who have lower
working memory capacity and poorer attentional
control are more prone to problematic mobile phone
use, and are less resilient to digital media distrac-
tion.23 The type of mobile e.g. branding, aesthetic
factors may also need to be carefully planned. How
the intervention is delivered will also matter, for
example whether the intervention is to be delivered
via software at home or whilst at a clinic.
There is however, further complication when con-
sidering placebo use, and that is how placebo effects
are measured.
The Placebo Effect measured
This is the output caused by the apparent action of
the placebo. This is greatly complicated by factors
that can influence measurement. The placebo effect
is often confused with other confounding factors in
experiments.15 Measured outcomes as a result of a
placebo trial may in fact be due to a multiplicity of
unintended factors.
For example, the Hawthorne or observer effect occurs
where individuals change their behaviour simply
because they believe they are being observed.29
A positive interpretation by participants of the
Hawthorne effect is known as the Demand effect;
participants think they know what experimenters
are looking for.29 If participants are presented with
information differently, e.g. positive or negative
delivery by an individual, this becomes the Halo
Effect.18 Where an intervention is out of the
ordinary, an occurrence that is common in the
mobile and digital technology field, behavior may
change simply because of the Novelty effect. The
Will Rogers phenomenon occurs where changes in
diagnostic criteria seemingly produce improvements
in prognosis for individuals, especially when diagno-
sis improves early detection and so patients appear
to live longer. Simpson’s Paradox occurs where
trends in experimental findings can be completely
changed if sub-groups are analyzed separately or
together, such as trends in data can also completely
disappear.
What we can see is that not only do treatment or
intervention protocols need to be carefully de-
signed, but that with the introduction of digital
technology additional confounders of attitudes,
objects and delivery potentially require further
planning before trials get underway.
Placebo in Complex Interventions Using Digital
Technology
Traditional placebo effects are based on an individ-
ual ingesting a drug, or taking part in an interven-
tion that is believed to be effective as a treatment.
For example, the participant agrees that they may be
getting absolutely nothing within a clinical trial, but
they may be willing to take that risk (e.g. new phone
based method of delivering cognitive behavioural
therapy) if the risks are offset by increased life
expectancy. However, if hidden factors surrounds a
digital object e.g. through a screen, a monitor or a
mobile, this makes placebo additionally complex,
and may not carry the same weight in terms of life
and death decisions. For example, the ‘on’ and ‘off’-
ness of digital technology is problematic; dummy
technology cannot be ‘on’, deliver therapeutic
effects, and deliver bogus therapy at the same time.
Some research has attempted to do exactly that,
replicate digital technology, yet give dummy feed-
back to the participant.
Heywood and Beale24 used EEG to look at the
difference between the delivery of a biofeedback
tool for children with Attention Deficit/Hyperactivity
disorder (ADHD). In the experimental condition
children with ADHD were given a standard EEG
biofeedback treatment that reflected their affective
state, designed to alter behaviours synonymous with
ADHD. This was alternated with a placebo proto-
col identical to the treatment but with averaged
EEG feedback from all participants and so not
linked to the individual’s real affective state, with
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the hypothesis that having real-time information
would enable individuals to recognize when they
were becoming hyperactive, or likely to lose interest.
The result was that the live EEG feedback produced
no difference to the placebo compared to baseline
levels and as a result reinforces the need to test out
the salient ingredients of any given intervention
when using digital technology. However, as is
discussed below, the use of a placebo without a
control condition lessens the power of findings.
Chittaro and Sioni25 developed a game that detects
a user’s level of stress and depression and then feeds
that back to the individual in the form of a 3D
virtual character which embodies the state of the
person, with the aim of influencing the person’s
affective state. In their placebo condition the user’s
stress level was measured by pseudo-randomly
taking into account real time readings from physio-
logical sensors. The experiment used two further
types of sensor, a single physiological sensor, which
measured skin conductance, and a second sensor
that detected four types of affective information,
skin conductance, heart rate, and the muscular
response of two muscle receptors. Their findings
showed that only the single physiological sensor was
better than the placebo condition, therefore the
placebo was the same as the multiple sensor in
allowing individuals to alter their affective state
based on biofeedback. In both of these experiments
the use of a placebo condition, or a dummy
treatment showed that digital treatment was not
effective.
Some work within tangible computing, and the
‘internet of things’26, a branch of computer science
that uses digital tags embedded within objects, has
attempted to use a control condition not as treat-
ment as usual, but as an experimental condition but
with digital technology simply turned off. Obviously
for screen-based digital technologies e.g. mobile,
tablet, multi-touch surfaces, technology being off is
problematic, however for technology that is within
the ‘internet of things’ this may have less impact.
In a number of novel experiments Hinske et al27,28
looked at a child’s play environment which was
augmented with RFID antennae and Dolby stereo.
In these experiments a toy, a Playmobil knight’s
castle was either used with digital augmentation
turned on or off. Both play environments were
therefore valid as they were using the same object,
but with only one augmented with digital feedback.
When comparing children’s play with the augmented
knight’s castle and with the knight’s castle, it was
found that the augmentation promoted more talking
and more interaction. In the augmented knight’s
castle there is a problem if a placebo condition was
tried in that there is no way the technology could
deliver the same effects experienced with the digital
technology in a bogus way, as children’s activity
with toys caused digital feedback to occur. In this
instance, activity dependent differences in digital
feedback confounded comparison between placebo
and real conditions.
More recently, Denisova and Cairns (2015)33 have
shown that a placebo effect can occur in digital
games when users are primed to expect certain
features of a game, which in due course resulted in
deeper immersion. When users thought artificial
intelligence was switched on during game use, even
though it was not, deeper immersion was reported.
In certain circumstances it is impossible to con-
struct a placebo using digital technology because
the technology is either on or off. Further, placebos
with digital technology are currently never ingested,
invasive, or part of the human body. A true digital
placebo might begin to have a place in experimen-
tation when digital tags are placed under the skin of
workers. This could be used in clinical settings with
slow-release drugs, controlled by digital technology,
or to investigate further the patient-clinician rela-
tionship if clinicians were tagged and then factors
affecting measurement such as the Hawthorne effect
were purposefully manipulated. The placebo object
may be useful if wearable technology is being used
to gather data about user head motion or stability,
eye gaze, gross motor function, especially if it is
impossible to tell if the technology is switched on
or not.
Conclusions
Whilst medicine still debates the impact of placebo,
it appears that there is a multi-faceted definition of
what constitutes placebo. Further, investigation into
cumulative effects of individuals receiving placebos
over time does not as yet show effective ways of
estimating the effect of placebo.11 Whilst the best
use of placebo employs RCT double blind method-
ology (e.g. BOTXN versus saline injections) with a
no-treatment control group, even this complicates
methodology by introducing a third group.11 There
is as yet mixed evidence for the placebo effects in
clinical trials, but evidence is growing for placebo
interventions being now statistically (but not
necessarily clinically) significant for ‘‘patient and
observer-reported continuous outcomes’’.19
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A placebo paradigm using digital technology may
only be useful in healthcare settings only if all sub-
factors are taken into consideration; the feelings and
perceptions of individuals, the measurements being
taken, the participant group, the interaction and
delivery of the placebo and the placebo object itself.
Mobile technology in medicine is bound to bring
with it a new type of meaning response, which will
require careful adjustment to counterbalance effects.
Surveying a population may be one way to begin to
understand hidden factors if a study is at risk, prior
biases could therefore be carefully considered before
beginning a trial. Checking the acceptability of a
new intervention through patient and public involve-
ment before trial may also reveal any hidden effects
that may occur. The uses of new methods of data
capture e.g. mini-RCTs35 where participants may be
in more than one experimental group depending on
activity, offers novel ways of accounting for individ-
ual variance. It is conceivable that groups could and
should be constructed within a trial based on prior
average daily smartphone use, age, demographics, or
whether their preferred mode of delivery is tablet
over smartphone. Ultimately the impact of hidden
effects of digital technology will come down to the
efficacy, method and planning of the trial, and as
long as software, human computer interaction
experts, and clinical teams work together closely
the ‘‘more hype than hope’’36 accusation aimed at
digital technology should not arise.
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